IP Library Granted Patent US 10,072,264
Granted Patent B2
US 10,072,264 · App. 15/395,993 · Granted Sep 11, 2018

RNA interference suppression of neurodegenerative diseases and methods of use

Inventors: Beverly L. Davidson (Iowa City, IA); Haibin Xia (Iowa City, IA); Qinwen Mao (Iowa City, IA); Henry Paulson (Iowa City, IA); Ryan Boudreau (Iowa City, IA); Scott Harper (Iowa City, IA)
Assignee: University of Iowa Research Foundation
C12N15/113C12N15/86A01K2217/05A61K38/00A61K48/00C12N2310/111C12N2310/14C12N2310/53C12N2310/531C12N2750/14143C12N2799/021C12N2799/022C12N2799/025
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,072,264
App. No.
15/395,993
Granted
Sep 11, 2018
Kind
B2
Abstract

The present invention is directed to small interfering RNA molecules (siRNA) targeted against nucleic acid sequence that encodes huntingtin or ataxin-1, and methods of using these siRNA molecules.

Claims (40)

1. An isolated RNA duplex comprising a first strand of RNA and a second strand of RNA, wherein the first strand comprises at least 15 contiguous nucleotides encoded by SEQ ID NO:97, and wherein the second strand is complementary to at least 12 contiguous nucleotides of the first strand.

2. The RNA duplex of claim 1 , wherein the duplex is between 15and 30 base pairs in length.

3. The RNA duplex of claim 1 , wherein the duplex is between 19 and 25 base pairs in length.

4. The RNA duplex of claim 1 , wherein the first and/or second strand further comprises an overhang region.

5. The RNA duplex of claim 1 , wherein the first and/or second strand further comprises a 3′ overhang region, a 5′ overhang region, or both 3′ and 5′ overhang regions.

6. The RNA duplex of claim 4 , wherein the overhang region is from 1 to 10nucleotides in length.

7. The RNA duplex of claim 1 , wherein the first strand and the second strand are operably linked by means of an RNA loop strand to form a hairpin structure comprising a duplex structure and a loop structure.

8. The RNA duplex of claim 7 , wherein the loop structure contains from 4 to 10nucleotides.

9. The RNA duplex of claim 7 , wherein the loop structure contains 4, 5 or 6nucleotides.

10. The RNA duplex of claim 7 , wherein the loop structure corresponds to SEQ ID NO:61 or SEQ ID NO:64.

11. An expression cassette comprising a nucleic acid encoding at least one strand of the RNA duplex of claim 1 .

12. The expression cassette of claim 11 , further comprising a promoter.

13. The expression cassette of claim 12 , wherein the promoter is a regulatable promoter.

14. The expression cassette of claim 12 , wherein the promoter is a constitutive promoter.

15. The expression cassette of claim 12 , wherein the promoter is a CMV, RSV, pol II or pol III promoter.

16. The expression cassette of claim 11 , wherein the expression cassette further comprises a polyadenylation signal.

17. The expression cassette of claim 16 , wherein the polyadenylation signal is a synthetic minimal polyadenylation signal.

18. The expression cassette of claim 11 , further comprising a marker gene.

19. A vector comprising the expression cassette of claim 11 .

20. A method of suppressing the accumulation of huntingtin or ataxin-1 in a cell comprising introducing into the cell in an amount sufficient to suppress accumulation of huntingtin or ataxin-1 in the cell

(a) a ribonucleic acid (RNA) duplex, wherein the RNA duplex comprises a first strand of RNA and a second strand of RNA, wherein the first strand comprises at least 15contiguous nucleotides encoded by SEQ ID NO:97 or SEQ ID NO:100, and wherein the second strand is complementary to at least 12 contiguous nucleotides of the first strand; or

(b) a vector comprising an expression cassette comprising a nucleic acid encoding a first strand of RNA and a second strand of RNA of an RNA duplex, wherein the first strand comprises at least 15 contiguous nucleotides encoded by SEQ ID NO:97 or SEQ ID NO:100.

21. The method of claim 20 , wherein the first strand comprises at least 15 contiguous nucleotides encoded by SEQ ID NO:97.

22. The method of claim 20 , wherein the first strand comprises at least 15 contiguous nucleotides encoded by SEQ ID NO:100.

23. The method of claim 20 , wherein the duplex is between 15 and 30 base pairs in length.

24. The method of claim 20 , wherein the duplex is between 19 and 25 base pairs in length.

25. The method of claim 20 , wherein the first and/or second strand further comprises an overhang region.

26. The method of claim 20 , wherein the first and/or second strand further comprises a 3′ overhang region, a 5′ overhang region, or both 3′ and 5′ overhang regions.

27. The method of claim 25 , wherein the overhang region is from 1 to 10 nucleotides in length.

28. The method of claim 20 , wherein the first strand and the second strand are operably linked by means of an RNA loop strand to form a hairpin structure comprising a duplex structure and a loop structure.

29. The method of claim 28 , wherein the loop structure contains from 4 to 10nucleotides.

30. The method of claim 28 , wherein the loop structure contains 4, 5 or 6nucleotides.

31. The method of claim 28 , wherein the loop structure corresponds to SEQ ID NO:61 or SEQ ID NO:64.

32. The method of claim 20 , wherein the expression cassette further comprises a promoter.

33. The method of claim 32 , wherein the promoter is a regulatable promoter.

34. The method of claim 32 , wherein the promoter is a constitutive promoter.

35. The method of claim 32 , wherein the promoter is a CMV, RSV, pol II or pol III promoter.

36. The method of claim 20 , the expression cassette further comprises a polyadenylation signal.

37. The method of claim 36 , wherein the polyadenylation signal is a synthetic minimal polyadenylation signal.

38. The method of claim 20 , wherein the vector further comprises a marker gene.

Assignments (3)
CONFIRMATORY LICENSE Recorded Feb 25, 2020
From: UNIVERSITY OF IOWA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 052005/0606 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2017
From: DAVIDSON, BEVERLY L.; BOUDREAU, RYAN; MAO, QINWEN; PAULSON, HENRY; XIA, HAIBIN
To: UNIVERSITY OF IOWA RESEARCH FOUNDATION
Reel/Frame 043915/0176 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2017
From: HARPER, SCOTT
To: UNIVERSITY OF IOWA RESEARCH FOUNDATION
Reel/Frame 043915/0267 →
Continuity (13)
Continuation 14931667 · Nov 3, 2015
Continuation 13920969 · Jun 18, 2013
Continuation 12963793 · Dec 9, 2010
Continuation 11597225
Continuation In Part 11048627 · Jan 31, 2005
Continuation In Part 10859751 · Jun 2, 2004
Continuation In Part 10738642 · Dec 16, 2003
Continuation In Part PCTUS0316887 · May 26, 2003
Continuation In Part 10430351 · May 5, 2003
Continuation 10322086 · Dec 17, 2002
Continuation In Part 10212322 · Aug 5, 2002
Continuation In Part PCTUS0316887 · May 26, 2003
Related Publication 20170335318A1 · Nov 23, 2017
Cited By (1)
US 12,331,296